company background image
PCR

PCC RokitaWSE:PCR Stock Report

Last Price

zł95.90

Market Cap

zł1.9b

7D

0.4%

1Y

70.0%

Updated

16 Jan, 2022

Data

Company Financials +
PCR fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance5/6
Financial Health3/6
Dividends3/6

PCR Stock Overview

PCC Rokita SA manufactures and distributes chemical products in Poland and internationally.

PCC Rokita Competitors

BASF

XTRA:BAS

€62.6b

Bayer

XTRA:BAYN

€51.7b

DuPont de Nemours

NYSE:DD

US$44.0b

Akzo Nobel

ENXTAM:AKZA

€17.6b

Price History & Performance

Summary of all time highs, changes and price drops for PCC Rokita
Historical stock prices
Current Share Pricezł95.90
52 Week Highzł102.60
52 Week Lowzł56.40
Beta1.23
1 Month Change7.75%
3 Month Change4.24%
1 Year Change70.04%
3 Year Change14.71%
5 Year Change42.45%
Change since IPO189.20%

Recent News & Updates

Sep 01
We Like These Underlying Return On Capital Trends At PCC Rokita (WSE:PCR)

We Like These Underlying Return On Capital Trends At PCC Rokita (WSE:PCR)

If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Typically, we'll...

Jun 14
Why PCC Rokita SA (WSE:PCR) Could Be Worth Watching

Why PCC Rokita SA (WSE:PCR) Could Be Worth Watching

PCC Rokita SA ( WSE:PCR ), is not the largest company out there, but it led the WSE gainers with a relatively large...

May 18
Are PCC Rokita SA (WSE:PCR) Investors Paying Above The Intrinsic Value?

Are PCC Rokita SA (WSE:PCR) Investors Paying Above The Intrinsic Value?

In this article we are going to estimate the intrinsic value of PCC Rokita SA ( WSE:PCR ) by taking the expected future...

Shareholder Returns

PCRPL ChemicalsPL Market
7D0.4%3.2%1.8%
1Y70.0%11.5%18.7%

Return vs Industry: PCR exceeded the Polish Chemicals industry which returned 11.5% over the past year.

Return vs Market: PCR exceeded the Polish Market which returned 18.7% over the past year.

Price Volatility

Is PCR's price volatile compared to industry and market?
PCR volatility
PCR Average Weekly Movement3.9%
Chemicals Industry Average Movement3.9%
Market Average Movement6.0%
10% most volatile stocks in PL Market11.5%
10% least volatile stocks in PL Market3.5%

Stable Share Price: PCR is less volatile than 75% of Polish stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: PCR's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
n/a1,678Wieslaw Klimkowskihttps://www.pcc.rokita.pl

PCC Rokita SA manufactures and distributes chemical products in Poland and internationally. The company offers chloralkali, raw materials, and intermediates; polyurethanes; specialty products; and surfactants products, as well as polyols, naphthalene, and phosphorus derivatives. It serves adhesives, agrochemicals, building and construction, case, chemical reagents, detergents, fire prevention, food and fuel industry, furniture, I&I cleaning, lubricants and metalworking fluids, base oils, metallurgical, mining and drilling, oilfield, packaging, paints and coatings, personal care, pharmaceuticals, plastics, power, printing ink, pulp and paper, raw materials and intermediates, refrigeration and household appliances, sports and recreation, tanning and textile, transportation, vehicle cleaning and care, and water and wastewater treatment industries.

PCC Rokita Fundamentals Summary

How do PCC Rokita's earnings and revenue compare to its market cap?
PCR fundamental statistics
Market Capzł1.90b
Earnings (TTM)zł294.33m
Revenue (TTM)zł2.03b

6.5x

P/E Ratio

0.9x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
PCR income statement (TTM)
Revenuezł2.03b
Cost of Revenuezł1.40b
Gross Profitzł631.51m
Expenseszł337.18m
Earningszł294.33m

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)14.83
Gross Margin31.16%
Net Profit Margin14.52%
Debt/Equity Ratio68.2%

How did PCR perform over the long term?

See historical performance and comparison

Dividends

3.8%

Current Dividend Yield

25%

Payout Ratio

Valuation

Is PCC Rokita undervalued compared to its fair value and its price relative to the market?

6.47x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: PCR (PLN95.9) is trading above our estimate of fair value (PLN89.44)

Significantly Below Fair Value: PCR is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: PCR is good value based on its PE Ratio (6.5x) compared to the Polish Chemicals industry average (11.8x).

PE vs Market: PCR is good value based on its PE Ratio (6.5x) compared to the Polish market (12.3x).


Price to Earnings Growth Ratio

PEG Ratio: PCR's earnings are forecast to decline next year, so we can't calculate its PEG ratio.


Price to Book Ratio

PB vs Industry: PCR is overvalued based on its PB Ratio (2x) compared to the PL Chemicals industry average (1x).


Future Growth

How is PCC Rokita forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

-33.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: PCR's earnings are forecast to decline over the next 3 years (-33.1% per year).

Earnings vs Market: PCR's earnings are forecast to decline over the next 3 years (-33.1% per year).

High Growth Earnings: PCR's earnings are forecast to decline over the next 3 years.

Revenue vs Market: PCR's revenue is expected to decline over the next 3 years (-3.9% per year).

High Growth Revenue: PCR's revenue is forecast to decline over the next 3 years (-3.9% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: PCR's Return on Equity is forecast to be low in 3 years time (13.4%).


Past Performance

How has PCC Rokita performed over the past 5 years?

-4.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: PCR has high quality earnings.

Growing Profit Margin: PCR's current net profit margins (14.5%) are higher than last year (5.2%).


Past Earnings Growth Analysis

Earnings Trend: PCR's earnings have declined by 4.3% per year over the past 5 years.

Accelerating Growth: PCR's earnings growth over the past year (301.4%) exceeds its 5-year average (-4.3% per year).

Earnings vs Industry: PCR earnings growth over the past year (301.4%) exceeded the Chemicals industry 35.7%.


Return on Equity

High ROE: PCR's Return on Equity (31%) is considered high.


Financial Health

How is PCC Rokita's financial position?


Financial Position Analysis

Short Term Liabilities: PCR's short term assets (PLN633.2M) exceed its short term liabilities (PLN478.8M).

Long Term Liabilities: PCR's short term assets (PLN633.2M) do not cover its long term liabilities (PLN751.5M).


Debt to Equity History and Analysis

Debt Level: PCR's net debt to equity ratio (49.1%) is considered high.

Reducing Debt: PCR's debt to equity ratio has increased from 63.3% to 68.2% over the past 5 years.

Debt Coverage: PCR's debt is well covered by operating cash flow (72.3%).

Interest Coverage: PCR's interest payments on its debt are well covered by EBIT (16.7x coverage).


Balance Sheet


Dividend

What is PCC Rokita current dividend yield, its reliability and sustainability?

3.83%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: PCR's dividend (3.83%) is higher than the bottom 25% of dividend payers in the Polish market (2.24%).

High Dividend: PCR's dividend (3.83%) is low compared to the top 25% of dividend payers in the Polish market (6.72%).


Stability and Growth of Payments

Stable Dividend: PCR has been paying a dividend for less than 10 years and during this time payments have been volatile.

Growing Dividend: PCR's dividend payments have increased, but the company has only paid a dividend for 7 years.


Current Payout to Shareholders

Dividend Coverage: With its low payout ratio (24.8%), PCR's dividend payments are well covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: PCR's dividends in 3 years are forecast to be covered by earnings (81.2% payout ratio).


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

12.0yrs

Average management tenure


CEO

Wieslaw Klimkowski

17yrs

Tenure

zł4,899,000

Compensation

Mr. Wieslaw Klimkowski serves as the President of the Management Boards at Rokita S.A. and Silesia-Kalk Sp. z o.o. Mr. Klimkowski served as Director of Investor Supervision & Group Development of PCC Rokit...


CEO Compensation Analysis

Compensation vs Market: Wieslaw's total compensation ($USD1.23M) is above average for companies of similar size in the Polish market ($USD322.51K).

Compensation vs Earnings: Wieslaw's compensation has increased by more than 20% in the past year.


Leadership Team

Experienced Management: PCR's management team is seasoned and experienced (12 years average tenure).


Board Members

Experienced Board: PCR's board of directors are considered experienced (6 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

PCC Rokita SA's employee growth, exchange listings and data sources


Key Information

  • Name: PCC Rokita SA
  • Ticker: PCR
  • Exchange: WSE
  • Founded: NaN
  • Industry: Specialty Chemicals
  • Sector: Materials
  • Implied Market Cap: zł1.904b
  • Shares outstanding: 19.85m
  • Website: https://www.pcc.rokita.pl

Number of Employees


Location

  • PCC Rokita SA
  • ul. Sienkiewicza 4
  • Brzeg Dolny
  • 56-120
  • Poland

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/01/16 18:04
End of Day Share Price2022/01/14 00:00
Earnings2021/09/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.